Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-707 in advanced gynecologic malignancies
CTR20242752Phase 2Active
- Sponsor
- 3SBio
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in endometrial cancer (EC), epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by 3SBio. Started Oct 2024; status: active.
02
Drugs
PF-08634404
03
Conditions
endometrial cancer (EC)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20242752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242752.